Associations - PIK3CA mutation

PIK3CA mutation PIK3CA mutation	HER2 Negative Breast Cancer HER2 Negative Breast Cancer	alpelisib Sensitive: B - Late Trials
PIK3CA mutation PIK3CA mutation	Breast Cancer Breast Cancer	BKM120 Sensitive: B - Late Trials
PIK3CA mutation PIK3CA mutation	Breast Cancer Breast Cancer	alpelisib Sensitive: B - Late Trials
PIK3CA mutation PIK3CA mutation	Triple Negative Breast Cancer Triple Negative Breast Cancer	GDC-0068 Sensitive: B - Late Trials
PIK3CA mutation PIK3CA mutation	Colorectal Cancer CRC	panitumumab Resistant: B - Late Trials
PIK3CA mutation PIK3CA mutation	HER2 Positive Breast Cancer HER2 Positive Breast Cancer	neratinib Resistant: B - Late Trials
PIK3CA mutation PIK3CA mutation	HER2 Positive Breast Cancer HER2 Positive Breast Cancer	lapatinib Resistant: B - Late Trials
PIK3CA mutation PIK3CA mutation	HER2 Positive Breast Cancer HER2 Positive Breast Cancer	trastuzumab Sensitive: B - Late Trials
PIK3CA mutation PIK3CA mutation	Colorectal Cancer CRC	atezolizumab + cobimetinib Sensitive: B - Late Trials
PIK3CA mutation PIK3CA mutation	HER2 Positive Breast Cancer HER2 Positive Breast Cancer	everolimus Sensitive: B - Late Trials
PIK3CA mutation PIK3CA mutation	Non Small Cell Lung Cancer NSCLC	erlotinib Resistant: B - Late Trials
PIK3CA mutation PIK3CA mutation	HER2 Positive Breast Cancer HER2 Positive Breast Cancer	trastuzumab + MEN1611 Sensitive: C2 – Inclusion Criteria
PIK3CA mutation PIK3CA mutation	Uterine Cancer Uterine Cancer	copanlisib Sensitive: C2 – Inclusion Criteria
PIK3CA mutation PIK3CA mutation	HER2 Positive Breast Cancer HER2 Positive Breast Cancer	MEN1611 Sensitive: C2 – Inclusion Criteria
PIK3CA mutation PIK3CA mutation	Breast Cancer Breast Cancer	palbociclib Sensitive: C2 – Inclusion Criteria
PIK3CA mutation PIK3CA mutation	Breast Cancer Breast Cancer	MEN1611 Sensitive: C2 – Inclusion Criteria
PIK3CA mutation PIK3CA mutation	Breast Cancer Breast Cancer	GDC-0032 Sensitive: C2 – Inclusion Criteria
PIK3CA mutation PIK3CA mutation	Squamous Cell Carcinoma of Head and Neck SCCHN	alpelisib Sensitive: C2 – Inclusion Criteria
PIK3CA mutation PIK3CA mutation	Hormone Receptor Positive Breast Cancer Hormone Receptor Positive Breast Cancer	alpelisib + fulvestrant Sensitive: C2 – Inclusion Criteria
PIK3CA mutation PIK3CA mutation	Non Small Cell Lung Cancer NSCLC	U3-1402 Sensitive: C3 – Early Trials
PIK3CA mutation PIK3CA mutation	Triple Negative Breast Cancer Triple Negative Breast Cancer	everolimus Sensitive: C3 – Early Trials
PIK3CA mutation PIK3CA mutation	Urothelial Cancer Urothelial Cancer	pembrolizumab Sensitive: C3 – Early Trials
PIK3CA mutation PIK3CA mutation	Squamous Cell Carcinoma of Head and Neck SCCHN	temsirolimus Sensitive: C3 – Early Trials
PIK3CA mutation PIK3CA mutation	Non Small Cell Lung Cancer NSCLC	X-396 Resistant: C3 – Early Trials
PIK3CA mutation PIK3CA mutation	Breast Cancer Breast Cancer	bevacizumab Sensitive: C3 – Early Trials
PIK3CA mutation PIK3CA mutation	Breast Cancer Breast Cancer	ribociclib Sensitive: C3 – Early Trials
PIK3CA mutation PIK3CA mutation	Hormone Receptor Positive Breast Cancer Hormone Receptor Positive Breast Cancer	fulvestrant + anastrozole Sensitive: C3 – Early Trials
PIK3CA mutation PIK3CA mutation	Breast Cancer Breast Cancer	CDK6 inhibitor Resistant: C3 – Early Trials
PIK3CA mutation PIK3CA mutation	Breast Cancer Breast Cancer	CDK4 inhibitor Resistant: C3 – Early Trials
PIK3CA mutation PIK3CA mutation	Liposarcoma Liposarcoma	copanlisib Sensitive: C3 – Early Trials
PIK3CA mutation PIK3CA mutation	Non Small Cell Lung Cancer NSCLC	osimertinib Resistant: C3 – Early Trials
PIK3CA mutation PIK3CA mutation	Estrogen Receptor Positive Breast Cancer Estrogen Receptor Positive Breast Cancer	letrozole Sensitive: C3 – Early Trials
PIK3CA mutation PIK3CA mutation	Colorectal Cancer CRC	trametinib + dabrafenib Sensitive: C3 – Early Trials
PIK3CA mutation PIK3CA mutation	Head and Neck Cancer Head and Neck Cancer	GDC-0032 Sensitive: C3 – Early Trials
PIK3CA mutation PIK3CA mutation	Gastric Cancer Gastric Cancer	nivolumab Sensitive: C3 – Early Trials
PIK3CA mutation PIK3CA mutation	Squamous Cell Carcinoma of Head and Neck SCCHN	cetuximab Resistant: C3 – Early Trials
PIK3CA mutation PIK3CA mutation	Lung Non-Small Cell Squamous Cancer Lung Non-Small Cell Squamous Cancer	GDC-0032 Sensitive: C3 – Early Trials
PIK3CA mutation PIK3CA mutation	Squamous Cell Carcinoma of Head and Neck SCCHN	cetuximab + alpelisib Sensitive: C3 – Early Trials
PIK3CA mutation PIK3CA mutation	Breast Cancer Breast Cancer	trastuzumab Resistant: C3 – Early Trials
PIK3CA mutation PIK3CA mutation	Colorectal Cancer CRC	cetuximab Resistant: C3 – Early Trials
PIK3CA mutation PIK3CA mutation	Solid Tumor Solid Tumor	LY2606368 + LY3023414 Sensitive: C3 – Early Trials
PIK3CA mutation PIK3CA mutation	HER2 Positive Breast Cancer HER2 Positive Breast Cancer	ado-trastuzumab emtansine Resistant: C3 – Early Trials
PIK3CA mutation PIK3CA mutation	Hormone Receptor Positive Breast Cancer Hormone Receptor Positive Breast Cancer	everolimus + exemestane Sensitive: C3 – Early Trials
PIK3CA mutation PIK3CA mutation	Colorectal Cancer CRC	FOLFOX Resistant: C3 – Early Trials
PIK3CA mutation PIK3CA mutation	Colorectal Cancer CRC	CAPOX Resistant: C3 – Early Trials
PIK3CA mutation PIK3CA mutation	HER2 Positive Breast Cancer HER2 Positive Breast Cancer	trastuzumab + alpelisib + LJM-716 Sensitive: C3 – Early Trials
PIK3CA mutation PIK3CA mutation	Non Small Cell Lung Cancer NSCLC	alpelisib Sensitive: C4 – Case Studies
PIK3CA mutation PIK3CA mutation	Ampulla of Vater Carcinoma Ampulla of Vater Carcinoma	everolimus Sensitive: C4 – Case Studies
PIK3CA mutation PIK3CA mutation	Ovarian Cancer Ovarian Cancer	CYH33 Sensitive: C4 – Case Studies
PIK3CA mutation PIK3CA mutation	Breast Cancer Breast Cancer	CYH33 Sensitive: C4 – Case Studies
PIK3CA mutation PIK3CA mutation	Gastric Cancer Gastric Cancer	alpelisib Sensitive: D – Preclinical
PIK3CA mutation PIK3CA mutation	Breast Cancer Breast Cancer	PP242 Sensitive: D – Preclinical
PIK3CA mutation PIK3CA mutation	Triple Negative Breast Cancer Triple Negative Breast Cancer	crizotinib + sunitinib Sensitive: D – Preclinical
PIK3CA mutation PIK3CA mutation	Triple Negative Breast Cancer Triple Negative Breast Cancer	gefitinib + everolimus Sensitive: D – Preclinical
PIK3CA mutation PIK3CA mutation	Non Small Cell Lung Cancer NSCLC	GDC-0941 Sensitive: D – Preclinical
PIK3CA mutation PIK3CA mutation	Estrogen Receptor Positive Breast Cancer Estrogen Receptor Positive Breast Cancer	ribociclib + SNS-510 Sensitive: D – Preclinical
PIK3CA mutation PIK3CA mutation	Estrogen Receptor Positive Breast Cancer Estrogen Receptor Positive Breast Cancer	palbociclib + SNS-510 Sensitive: D – Preclinical
PIK3CA mutation PIK3CA mutation	HER2 Positive Breast Cancer HER2 Positive Breast Cancer	CCT128930 Sensitive: D – Preclinical
PIK3CA mutation PIK3CA mutation	Ovarian Cancer Ovarian Cancer	CERC-006 Sensitive: D – Preclinical
PIK3CA mutation PIK3CA mutation	Breast Cancer Breast Cancer	TAK-228 Sensitive: D – Preclinical
PIK3CA mutation PIK3CA mutation	Colon Cancer Colon Cancer	PF-05212384 + PD-0325901 Sensitive: D – Preclinical
PIK3CA mutation PIK3CA mutation	Thyroid Gland Carcinoma Thyroid Gland Carcinoma	temsirolimus + MK-2206 Sensitive: D – Preclinical
PIK3CA mutation PIK3CA mutation	Endometrial Cancer Endometrial Cancer	temsirolimus Sensitive: D – Preclinical
PIK3CA mutation PIK3CA mutation	Endometrial Cancer Endometrial Cancer	GDC-0941 Sensitive: D – Preclinical
PIK3CA mutation PIK3CA mutation	Endometrial Cancer Endometrial Cancer	RTB101 Sensitive: D – Preclinical
PIK3CA mutation PIK3CA mutation	Head and Neck Cancer Head and Neck Cancer	celecoxib Sensitive: D – Preclinical
PIK3CA mutation PIK3CA mutation	Breast Cancer Breast Cancer	trastuzumab + MEN1611 Sensitive: D – Preclinical
PIK3CA mutation PIK3CA mutation	Thyroid Gland Carcinoma Thyroid Gland Carcinoma	MK-2206 Sensitive: D – Preclinical
PIK3CA mutation PIK3CA mutation	Gastric Cancer Gastric Cancer	AZD5363 Sensitive: D – Preclinical
PIK3CA mutation PIK3CA mutation	Squamous Cell Carcinoma of Head and Neck SCCHN	tipifarnib Sensitive: D – Preclinical
PIK3CA mutation PIK3CA mutation	Squamous Cell Carcinoma of Head and Neck SCCHN	cetuximab + AZD8055 Sensitive: D – Preclinical
PIK3CA mutation PIK3CA mutation	Squamous Cell Carcinoma of Head and Neck SCCHN	GDC-0032 Sensitive: D – Preclinical
PIK3CA mutation PIK3CA mutation	Melanoma Melanoma	vemurafenib Resistant: D – Preclinical
PIK3CA mutation PIK3CA mutation	Breast Cancer Breast Cancer	abemaciclib + alpelisib Sensitive: D – Preclinical
PIK3CA mutation PIK3CA mutation	Cervical Cancer Cervical Cancer	neratinib + copanlisib Sensitive: D – Preclinical
PIK3CA mutation PIK3CA mutation	Breast Cancer Breast Cancer	mTORC1 inhibitor Sensitive: D – Preclinical
PIK3CA mutation PIK3CA mutation	Triple Negative Breast Cancer Triple Negative Breast Cancer	epirubicin Resistant: D – Preclinical
PIK3CA mutation PIK3CA mutation	Endometrial Cancer Endometrial Cancer	GDC-0068 Sensitive: D – Preclinical
PIK3CA mutation PIK3CA mutation	Adenoid Cystic Carcinoma Adenoid Cystic Carcinoma	tretinoin Sensitive: D – Preclinical
PIK3CA mutation PIK3CA mutation	Endometrial Cancer Endometrial Cancer	LY3023414 Sensitive: D – Preclinical
PIK3CA mutation PIK3CA mutation	Colorectal Cancer CRC	ribociclib + alpelisib Sensitive: D – Preclinical